VYGR - Voyager Therapeutics Inc logo

Voyager Therapeutics Inc

VYGR

Voyager Therapeutics develops genetic therapies for neurological diseases, including VY1706 for Alzheimer's and treatments for Huntington's and ALS. It utilizes an AAV capsid discovery platform and partners with major pharmaceutical companies for broader applications.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$223today

Score Overview

1 Year
Score
Net Growth10.02%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-14.65%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.0
Net Growth-63.15%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-7.90%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-168.03%
Net Trend50%
Net Income Consistency
Rev Growth142.33%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-263.06%
Net Trend45%
Net Income Consistency
Rev Growth98.79%
Rev Trend36%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Voyager Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on all available years of fundamentals. VYGR does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-01
$ 2.67โ€”
1 Year2025-10-01
$ 4.68-42.84%
5 Years2021-10-01
$ 2.612.49%
10 Years2016-09-30
$ 12.01-77.73%
All Time2015-11-11
$ 17.75-84.93%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 34M-$ 107M$ 116M
2025$ 40M-$ 119M$ 196M
2024$ 80M-$ 65M$ 266M
2023$ 250M$ 132M$ 230M
2022$ 40M-$ 46M$ 118M
2021$ 37M-$ 66M$ 132M
2020$ 171M$ 36M$ 181M
2019$ 104M-$ 40M$ 281M
2018$ 7M-$ 88M$ 155M
2017$ 10M-$ 70M$ 169M
2016$ 14M-$ 40M$ 174M
IPO2015$ 17M-$ 29M$ 224M
VYGR - Voyager Therapeutics Inc logo

Voyager Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 171M to $ 40M and net income went from $ 36M to -$ 119M. Revenue increased in 2 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 17M to $ 40M and net income went from -$ 29M to -$ 119M. Revenue increased in 4 of those 10 years; net income in 5.

Voyager Therapeutics Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Explore VYGR with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies